Virpax Pharmaceuticals Inc (VRPX) — Cash Flow-to-Debt Ratio
Virpax Pharmaceuticals Inc (VRPX) has a Cash Flow-to-Debt Ratio of -1.16x as of December 2024, meaning its operating cash flow of $-2.87 Million could theoretically repay -1% of its total liabilities ($2.47 Million) in one year. See Virpax Pharmaceuticals Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Virpax Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Virpax Pharmaceuticals Inc across 7 annual periods. Also explore Virpax Pharmaceuticals Inc (VRPX) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Virpax Pharmaceuticals Inc (2018–2024)
Year-by-year debt coverage analysis for Virpax Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Virpax Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -6.77x | $-16.71 Billion | $2.47 Billion | ▼ -428.5% |
| 2023 | -1.28x | $-9.85 Million | $7.69 Million | ▲ +77.8% |
| 2022 | -5.77x | $-17.85 Million | $3.09 Million | ▲ +17.2% |
| 2021 | -6.97x | $-14.54 Million | $2.09 Million | ▼ -2254.8% |
| 2020 | -0.30x | $-1.38 Million | $4.68 Million | ▲ +27.4% |
| 2019 | -0.41x | $-1.13 Million | $2.78 Million | ▲ +71.6% |
| 2018 | -1.43x | $-1.80 Million | $1.25 Million | — |